Search Results

You are looking at 1 - 10 of 150 items for :

  • "ipilimumab" x
  • Refine by Access: All x
Clear All
Full access

Neelima N. Nallapaneni, Rajesh Mourya, Vijaya Raj Bhatt, Sakshi Malhotra, Apar Kishor Ganti, and Ketki K. Tendulkar

-related adverse events associated with ipilimumab Describe the unusual presentation of rare complications associated with ipilimumab such as hypophysitis and uveitis Ipilimumab is a recombinant fully human monoclonal immunoglobulin that blocks cytotoxic T

Full access

Shailender Bhatia and John A. Thompson

disease met with failure in the past, and a pressing need existed for successful new therapies. However, this changed recently with the successful investigations of ipilimumab and vemurafenib, with both therapies associated with significantly improved

Full access

Matthew Zibelman and Anthony J. Olszanski

/L). Due to his history of prostate cancer, the patient was not eligible for a clinical trial and he was started on treatment with the cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitor ipilimumab at 3 mg/kg. The patient tolerated the first

Full access

Michelle T. Ashworth and Adil Daud

lymphadenopathy, and a subxiphoid nodule. Because vemurafenib was by this time FDA-approved and readily available, it was immediately restarted. Treatment was also initiated with the anti-CTLA4 antibody ipilimumab, 3 mg/kg intravenously every 3 weeks for 4 doses

Full access

Dung T. Le and Elizabeth M. Jaffee

With the approvals of sipuleucel-T and ipilimumab, immunotherapy has become a treatment option for more oncology patients. Sipuleucel-T is an autologous cellular product immunotherapy used to prime tumor antigen-specific T cells, and ipilimumab

Full access

Rahel Demisse, Neha Damle, Edward Kim, Jun Gong, Marwan Fakih, Cathy Eng, Leslie Oesterich, Madison McKenny, Jingran Ji, James Liu, Ryan Louie, Kit Tam, Sepideh Gholami, Wissam Halabi, Arta Monjazeb, Farshid Dayyani, and May Cho

instability–high (MSI-H). 2 , 3 The immune checkpoint inhibitors pembrolizumab, nivolumab, and combination nivolumab/ipilimumab have been approved in dMMR or MSI-H metastatic CRC that is refractory or intolerant to standard therapies. 4 – 7 However, the

Full access

John A. Thompson

ipilimumab, an immunomodulatory drug, Dr. Thompson noted that “for the first time, we are starting to see a flat [ie, plateauing] survival curve.” Approximately 20% of patients survive for 5 years, he noted. The second-line study by Hodi et al 1 found that

Full access

John A. Thompson

monoclonal antibody directed to the immune checkpoint receptor cytotoxic T-lymphocyte antigen 4 (CTLA4) ipilimumab was approved by the FDA. Dr. Thompson briefly reviewed the long-term survival data with ipilimumab. 3 He added, “We are now seeing a tail in

Full access

Steven M. Blum, William R. Jeck, Lindsay Kipnis, Ronald Bleday, Jonathan A. Nowak, and Matthew B. Yurgelun

) MRI of the pelvis after combined therapy with ipilimumab and nivolumab showing evidence of a response. (C) Sigmoid colon resection specimen with pT4b adenocarcinoma (bracket) and numerous polyps (arrows). Pathologic examination revealed an 8

Full access

Pooja Ghatalia and Elizabeth R. Plimack

% (24% in the PD-L1–high subgroup vs 14% in the PD-L1–low subgroup), including 6% patients with CR. 18 Nivolumab/Ipilimumab CheckMate 032 is an open-label, multicohort phase I/II trial in previously treated patients with metastatic urothelial cancer